Latest Biology Technology from Bio-Medicine.Org

Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results

Fri, 10 Feb 2012 08:54:29 MST

HYDERABAD, India, Feb. 10, 2012 /- Neuland Laboratories Ltd., (NSE: NEULANDLAB; BOM: 524558) a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract research and manufacturing services to customers located in 85 countries, today announced financial results for the third quarter of fiscal year (FY) 2012, ended December...

Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16

Fri, 10 Feb 2012 08:53:32 MST

BETHESDA, Md., Feb. 10, 2012 /- Spherix Incorporated (NASDAQ: SPEX) -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies -- today announced that Dr. Claire Kruger, Chief Executive Officer, will present to...

Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012

Fri, 10 Feb 2012 05:52:14 MST

ANAHEIM, Calif., Feb. 10, 2012 /- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) announced today that executive management will present at the Leerink Swann Global Healthcare Conference to be held on February 15-16, 2012 in New York. Steve Cartt, Executive Vice President and Chief Business Officer, is scheduled to present an overview of the Company on Thursday, Februar...

Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer

Fri, 10 Feb 2012 12:31:50 MST

LONDON, February 10, 2012 /- -- Tony Sedgwick steps up to Chief Executive Officer from Chief Business Officer -- -- Thomas Christély resigns as a Director of the Company -- Silence Therapeutics plc (AIM: SLN) ("Silence" or "the Company"), a leading RNA interference (RNAi) therapeutics company, announces today the promotion of Tony Sedgwick PhD, FRCPath to...

Orexigen Therapeutics to Present at Upcoming Conferences

Thu, 09 Feb 2012 08:37:42 MST

SAN DIEGO, Feb. 9, 2012 /- Orexigen ® Therapeutics, Inc. (Nasdaq: OREX ) today announced that management will be presenting at two upcoming investor conferences. The details are as follows: The 14th Annual BIO CEO & Investor Conference Date: February 13, 2012 Time: 1:30pm Eastern Time Location: Waldorf Astoria, New York Speaker: Michael Narach...

Ambit Biosciences to Present at Two Upcoming Investor Conferences

Thu, 09 Feb 2012 08:37:20 MST

SAN DIEGO, Feb. 9, 2012 /- Ambit Biosciences today announced that Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib, at two upcoming investor conferences at the Waldorf Astoria in New York City. 14th Annual BIO CEO & Investor Conference...

Stevenage Bioscience Catalyst Opens With Exciting Year Ahead

Thu, 09 Feb 2012 08:36:36 MST

STEVENAGE, England, February 9, 2012 /- First tenant moves in Stevenage Bioscience Catalyst (SBC), the UK's first open innovation bioscience campus, is pleased to announce that it is now open for business. In addition, it has welcomed its first tenant, Aptiv Solutions , which has taken space in the Incubator building. SBC expects its first year of operation to be a busy one - d...

Micross Components Hosts Stop on "Drive for Innovation" Tour

Thu, 09 Feb 2012 08:36:03 MST

ORLANDO, Fla., Feb. 9, 2012 /- Micross Components, a leading global provider of distributed and specialty electronic solutions, is pleased to announce its participation in the "Drive for Innovation" tour, sponsored by Avnet Express and UBM Electronics. Included as a "pit stop" during the tour's recent swing through Central Florida, Micross was selected because of its role in po...

Mesenchymal Stem Cells Have New Cell Culture Environment

Wed, 08 Feb 2012 08:40:39 MST

BILLERICA, Mass., Feb. 8, 2012 /- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of the new BD Mosaic™ Mesenchymal Stem Cell Serum-Free (hMSC SF), a complete cell culture environment for human mesenchymal stem cells (hMSCs) derived from bone marrow. The BD Mosaic hMSC cell culture environment is designed to provide cell exp...

Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012

Wed, 08 Feb 2012 08:40:05 MST

ROCKVILLE, Md., Feb. 8, 2012 /- Neuralstem, Inc. (NYSE Amex: CUR ) announces that President and CEO Richard Garr will present at the 14th Annual BIO CEO & Investor Conference 2012 in New York City on Monday, February 13, at 3:00 p.m. EST. Garr will present a business overview, and an update on the company's ongoing clinical trials in both its cell therapy and pharmaceutic...

New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications

Wed, 08 Feb 2012 12:01:27 MST

IPSWICH, Mass. and LA JOLLA, Calif., Feb. 7, 2012 /- New England Biolabs, Inc. (NEB) and Synthetic Genomics, Inc. (SGI) jointly announce that they have entered into a licensing agreement whereby NEB will introduce a master mix based on Gibson Assembly™, a revolutionary technology developed by Dr. Daniel Gibson and his colleagues at the J. Craig Venter Institute (JCVI...

Stanford engineers weld nanowires with light

Mon, 06 Feb 2012 07:21:42 MST

One area of intensive research at the nanoscale is the creation of electrically conductive meshes made of metal nanowires. Promising exceptional electrical throughput, low cost and easy processing, engineers foresee a day when such meshes are common in new generations of touch-screens, video displays, light-emitting diodes and thin-film solar cells. Standing in the way, however, is a m...

The butterfly effect in nanotech medical diagnostics

Mon, 06 Feb 2012 07:21:00 MST

Tiny metallic nanoparticles that shimmer in the light like the scales on a butterfly's wing are set to become the color-change components of a revolutionary new approach to point-of-care medical diagnostics, according to a study published in International Journal of Design Engineering . Thomas Schalkhammer and colleagues at Attophotonics Biosciences GmbH in Austria are working with Roland...

Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook

Mon, 06 Feb 2012 03:55:37 MST

REDWOOD CITY, Calif., Feb. 6, 2012 /- Genomic Health, Inc. (Nasdaq: GHDX ) today reported financial results and business progress for the year ended December 31, 2011. Total revenue for the year ended December 31, 2011 increased to $206.1 million, compared with $178.1 million in 2010, an increase of 16 percent. Product revenue was $204.8 million, compared with $174....

Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference

Mon, 06 Feb 2012 03:54:32 MST

SAN DIEGO, Feb. 6, 2012 /- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 14th Annual BIO CEO & Investor Conference in New York. The live presentation takes place on Monday, February 13 at 11:30 a.m. Eastern Time / 8:30 a.m. Pacific Time.&#...

Dietary Supplements Extensively Regulated, Say Authors of New Article

Mon, 06 Feb 2012 03:54:20 MST

AUSTIN, Texas, Feb. 6, 2012 /PRNewswire-USNewswire/ -- Dietary supplements are subject to a wide array of federal government regulations in the United States, according to a new report published by the nonprofit American Botanical Council (ABC). The article notes numerous authorities to regulate dietary supplements that are granted to the U.S. Food and Drug Administration (FDA) and the Federal...

Statewide Network of Angel Investor Groups Announced in Alabama

Mon, 06 Feb 2012 12:17:49 MST

HUNTSVILLE, Ala., Feb. 6, 2012 /- The Angel Investor Management (AIM) Group announced today the formation of the Central Alabama Angel Network (CANN) to serve the capital needs of entrepreneurs and investors in a seven-county region. "The Angel Investor Management Group is bringing together a single network of angel investor groups in Alabama. By banding together to share th...

BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials

Mon, 06 Feb 2012 12:17:04 MST

INDIANAPOLIS, Feb. 6, 2012 /- BioStorage Technologies, a global provider of comprehensive sample management solutions, biomaterial storage and cold chain logistics for the bioscience industry, will host its Global Sample Management Benchmarking Workshop at Partnerships in Clinical Trials on Tuesday, March 6, 2012 at the Marriott World Center in Orlando, Florida. The 2-...

Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer

Mon, 06 Feb 2012 09:28:56 MST

WASHINGTON and NEW YORK, Feb. 6, 2012 /- Accelerate Brain Cancer Cure (ABC2) and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer. The collaboration will explore the capabilities of Exosome RNA biofluid-based...

Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Mon, 06 Feb 2012 09:28:09 MST

RESEARCH TRIANGLE PARK, N.C., Feb. 6, 2012 /- Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients. CMX001 is a broad spectrum Lipid-Antiviral-Conjugate co...